DENVER, Jan. 27, 2021 -- Theralink® Technologies - (OTC: OBMP) ("Theralink" or the "Company"), a precision medicine molecular...
DENVER, Colorado — January 6, 2021 —Theralink Technologies (OTC: OBMP) (“Theralink” or the “Company”), a molecular pro...
DENVER, Colorado — November 16, 2020 —Theralink Technologies (OTC: OBMP) (“Theralink” or the “Company”), a precision o...
DENVER, Colorado — September 29, 2020 —Theralink Technologies (OTC: OBMP) (“Theralink” or the “Company”), a molecular...
DENVER, Colorado — September 24, 2020 —Theralink Technologies (OTC: OBMP) (“Theralink” or the “Company”), fo...
Golden, Colorado – September 15th, 2020 – Theralink Technologies, Inc., a molecular profiling company (OTC: OBMP), today annou...
Mick Ruxin, M.D., President and CEO of Theralink, will present at the H.C. Wainwright 22nd Annual Global Investment Conference to...
DENVER, Colorado — September 9, 2020 — OncBioMune d/b/a Theralink Technologies (OTC: OBMP) (“Theralink” or the “Compan...
Expects to Begin Receiving, Testing and Billing for Patient’s Breast Cancer Tumor Specimens in Q4 2020 -- DENVER, Colorado...
DENVER, Colorado — August 25, 2020 — OncBioMune d/b/a Theralink Technologies (OTC: OBMP) (“Theralink” or the “Company...